Should patients starting biologics be screened for COVID-19?
- PMID: 32632031
- DOI: 10.1136/annrheumdis-2020-218437
Should patients starting biologics be screened for COVID-19?
Keywords: antirheumatic agents; autoimmune diseases; biological therapy; immune system diseases; tumor necrosis factor inhibitors.
Conflict of interest statement
Competing interests: None declared.
Comment in
-
Response to: 'Should patients starting biologics be screened for COVID-19?' by Cardenas-de la Garza et al.Ann Rheum Dis. 2022 Aug;81(8):e151. doi: 10.1136/annrheumdis-2020-218470. Epub 2020 Jul 22. Ann Rheum Dis. 2022. PMID: 32699038 No abstract available.
Comment on
-
EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2.Ann Rheum Dis. 2020 Jul;79(7):851-858. doi: 10.1136/annrheumdis-2020-217877. Epub 2020 Jun 5. Ann Rheum Dis. 2020. PMID: 32503854
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
